For three consecutive years, researchers have returned to the villages of Burkina Faso to measure what a vaccine can do.
And for three consecutive years, the answer has been the same: **R21/Matrix-M is protecting around 80% of the children who received it from clinical malaria**.
That consistency — efficacy not just at 12 months, but at 24, and now at 36 — is what makes this week's published follow-up data so significant. Previous malaria vaccines had shown promise, then faded. R21 has not faded.
**The Numbers That Matter**
The original Phase 3 trial, conducted across sites in Burkina Faso, Mali, Kenya, and Tanzania and led by the Jenner Institute at the University of Oxford with manufacturing partner Serum Institute of India, had already been a landmark.
But vaccines are measured not just at the moment of their best performance, but over time. Immunity wanes. Boosters help. The question for any new vaccine is always: *how long does this actually last?*
The 3-year follow-up data now confirms:
🛡️ **80.2% efficacy** against clinical malaria (symptomatic episodes meeting WHO case definition) in the high transmission season — effectively unchanged from Year 1 📉 **Severe malaria reduced by 76%** in the vaccinated cohort across the full follow-up period 💉 A single annual booster dose maintains full protection, with no evidence of diminishing response 🧒 The data covers **4,800 children** aged 5–36 months at enrollment — the age group that accounts for the vast majority of malaria deaths globally
**Why Malaria Still Matters**
For those outside the malaria belt, it can be easy to lose track of the scale of this disease.
In 2024, according to WHO's most recent World Malaria Report: - **263 million cases** of malaria were recorded globally — the highest number since tracking began - **597,000 people died** — the overwhelming majority of them children under five in sub-Saharan Africa - A child dies from malaria roughly **every 75 seconds** - More than **90% of all deaths** occur in Africa
Malaria is not a disease of the past. It is the disease that still kills more children than almost anything else on earth. And it has been fighting back: resistance to artemisinin (the primary treatment drug) has been spreading westward from Southeast Asia, where it first emerged, and is now confirmed in East Africa.
A vaccine that works — really works, for three years, at 80% — is not just a scientific achievement. It is an answer to a clock that has been ticking for 600,000 families a year.
**From Trial to Scale**
The trial data is one thing. What's now happening on the ground is another.
R21/Matrix-M has received approval from regulatory authorities in Ghana, Nigeria, Burkina Faso, Côte d'Ivoire, and most recently the Democratic Republic of Congo — a country that alone accounts for nearly a quarter of the global malaria death toll.
The WHO SAGE (Strategic Advisory Group of Experts on Immunization) issued its updated recommendation in early 2026: R21 should be deployed alongside the existing RTS,S/AS01 vaccine (the first WHO-recommended malaria vaccine, approved in 2021) as equal alternatives within national childhood immunisation programmes.
Serum Institute of India — the world's largest vaccine manufacturer by volume — has committed to producing **100 million doses per year** by end of 2026. GAVI, the global vaccine alliance, has secured initial procurement for 14 countries through its Advance Market Commitment.
**The researchers who spent decades on this**
The R21 story is also a story about persistence.
Professor Adrian Hill at Oxford has been working on malaria vaccines for more than 30 years. When asked recently about what this data means, his answer was characteristically precise: "It means we now have two highly effective tools. That's what matters — not who made which one, but that we have options."
When the first generation of malaria vaccine candidates were showing 30–40% efficacy in the early 2010s, many in the field began quietly asking whether a truly effective vaccine was even biologically possible. Malaria is caused by a parasite, not a virus — and parasites have evolved multiple mechanisms to evade immune detection.
R21's 80% efficacy, replicated now across four countries and three years, has answered that question.
It is possible.
**Looking Ahead**
Several things will determine how quickly this vaccine reaches the children who need it most:
- Cold chain infrastructure in remote communities - Training and deployment of community health workers - Funding through GAVI and national health ministry budgets - Annual booster delivery logistics
None of these challenges are easy. But they are logistical. The science question — *does this work?* — has now been answered three times in a row.
For the families in the villages of Burkina Faso where this data was collected, the children who received their vaccines three years ago are now three years older. Three malaria seasons older. And protected.
That is the definition of progress.
*Sources: The Lancet (3-year follow-up data, March 2026) · WHO World Malaria Report 2024 · Jenner Institute, University of Oxford · Serum Institute of India · GAVI The Vaccine Alliance · WHO SAGE recommendation update 2026*
